Resources

Pulmonary Arterial Hypertension Causes and Treatments

Research Objectives:

  • Understand the current pulmonary arterial hypertension (PAH) patient and treatment landscape
  • Explore physician understanding of new treatments in development for PAH and their expectations

Methodology:
Method: 8-minute MicroSurvey via InCrowd
Crowds: US Cardiologists, US Pulmonologists
Sample Size: n=50
Fielding Period: January 30, 2019
Screening Criteria: Qualified respondents are US-based Cardiologists and Pulmonologists who…
• Have at least five PAH patients under their care
• Are aware of products in development for the treatment of PAH

Two key findings:

  • Most physicians feel that increased patient survival, improved health-related quality of life, and improved functional class are the most important clinical trial endpoints for new PAH treatments.
  • Almost half of physicians agree that the ideal mechanism of action (MOA) for new PAH drugs in development should be selective pulmonary vasodilation.

Download the full report now!

Please fill out the form below to access this content

Name(Required)
Consent
This field is for validation purposes and should be left unchanged.

Related Resources

The Impact of Technology on Mental Healthcare

The Impact of Technology on Mental Healthcare

Exploring Psychiatrist Opinions and Expectations Around the Rise in Digital Therapeutics to Treat Mental Health The National Institutes of Health (NIH) believe “technology has opened a new frontier in mental health support,” but questions remain around how...

read more
ESMO 2022 Real-Time Roundup

ESMO 2022 Real-Time Roundup

The 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) took place in person from September 9th to the 13th. InCrowd wanted to learn from those Medical Oncologists and Hematology-Oncologists who attended the following two objectives: Explore which...

read more
ASCO 2022 Real-Time Roundup

ASCO 2022 Real-Time Roundup

The 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in person from June 3rd to the 7th. InCrowd wanted to learn from those oncologists who attended the following two objectives: Explore which tumor type/track had the most exciting...

read more